Chimerix, Inc.

309 articles about Chimerix, Inc.

• Chimerix Announces Positive Topline Results for ONC201 in Recurrent H3 K27M-mutant Glioma

  11/4/2021

  Chimerix, a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, reported positive topline data from its 50-patient efficacy analysis of ONC201 for the treatment of recurrent H3 K27M-mutant glioma.

• Chimerix to Present at Credit Suisse 30th Annual Healthcare Conference

  11/1/2021

  Chimerix  today announced that Mike Sherman, Chief Executive Officer of Chimerix, will present a corporate overview at the Credit Suisse 30th Annual Healthcare Conference on Monday, November 8, 2021 at 9:40 a.m. ET.

• Chimerix to Report Third Quarter 2021 Financial Results and Provide an Operational Update on November 4, 2021

  10/28/2021

  Chimerix today announced that it will host a live conference call and audio webcast on Thursday, November 4, 2021 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2021, and to provide an operational update.

• Cantex Pharmaceuticals Announces Sale of Equity Interest in Chimerix, Inc.

  9/14/2021

  Cantex Pharmaceuticals, Inc. ("Cantex") today announced that it has sold 6.5 million shares of Chimerix, Inc.

• Chimerix to Present at H.C. Wainwright 23rd Annual Global Investment Conference

  9/7/2021

  Chimerix announced that Mike Sherman, Chief Executive Officer of Chimerix and Mike Andriole, Chief Financial and Business Officer of Chimerix, will participate in a pre-recorded fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference that will be made available on Monday, September 13, 2021 at 7:00 a.m. ET.

• Chimerix Reports Second Quarter 2021 Financial Results and Provides Operational Update

  8/5/2021

  Chimerix, a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, reported financial results for the second quarter ended June 30, 2021 and provided an operational update.

• Chimerix to Present at 2021 Wedbush PacGrow Healthcare Conference

  8/3/2021

  Chimerix, a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced that Mike Sherman, Chief Executive Officer, will participate in a panel discussion at the 2021 Wedbush PacGrow Healthcare Conference on Tuesday, August 10, 2021 at 10:55 a.m. ET.

• Chimerix to Report Second Quarter 2021 Financial Results and Provide an Operational Update on August 5, 2021

  7/29/2021

  Chimerix announced that it will host a live conference call and audio webcast on Thursday, August 5, 2021 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2021, and to provide an operational update.

• Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox– First smallpox antiviral approved for all age groups, including infants, and patients who have difficulty swallowing –

  6/4/2021

  Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted TEMBEXA ® (brincidofovir) tablets and oral suspension approval for the treatment of smallpox.

• Chimerix to Present at Jefferies Virtual Healthcare Conference - May 25, 2021

  5/25/2021

  Chimerix, a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced that Mike Sherman, Chief Executive Officer of Chimerix, will present a corporate overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 10:00 a.m. ET.

• Chimerix Announces Upcoming Presentations at the American Society of Clinical Oncology 2021 Annual Meeting

  5/19/2021

  Chimerix, a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced upcoming oral and poster presentations at the American Society of Clinical Oncology 2021 Annual Meeting, which will be held virtually June 4-8, 2021.

• Chimerix to Present at Cowen and Company 2nd Annual Virtual Oncology Innovation Summit

  5/13/2021

  Chimerix, a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced that Mike Sherman, Chief Executive Officer, and Mike Andriole, Chief Business and Financial Officer, will participate in a fireside chat at the Cowen and Company 2nd Annual Virtual Oncology Innovation Summit on Thursday, May 20, 2021 at 10:00 a.m. ET.

• Chimerix Reports First Quarter 2021 Financial Results and Provides Operational Update

  5/6/2021

  – BCV PDUFA Date Set for July 7 and ONC201 Blinded Independent Central Review Expected in Second Half of 2021 – – DSTAT COVID 19 Trial Advances to Cohort 3 at Higher Dose – – Conference Call at 8:30 a.m. ET Today

• Chimerix to Report First Quarter 2021 Financial Results and Provide an Operational Update on May 6, 2021

  4/29/2021

  Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Thursday, May 6, 2021 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2021, and to provide an operational update.

• Chimerix Appoints Vicki Vakiener to Board of Directors

  4/26/2021

  Chimerix, a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced the appointment of Vicki Vakiener to its Board of Directors, effective immediately.

• Chimerix to Present at Virtual H.C. Wainwright Global Life Sciences Conference

  3/2/2021

  Chimerix, a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced that Mike Sherman, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright Global Life Sciences Conference made available on Tuesday, March 9, 2021 at 7:00 a.m. ET.

• Chimerix Reports Promising Topline Results from First Cohort of a Randomized COVID-19 Trial with DSTAT

  2/25/2021

  Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, reported topline results today from the first cohort of its randomized, double-blind, placebo-controlled Phase 2/3 study in hospitalized patients with Acute Lung Injury (ALI) and COVID-19 infection.

• Chimerix Reports Fourth Quarter and Year End 2020 Financial Results and Provides Operational Update

  2/25/2021

  – Acquisition of Oncoceutics Adds Late-Stage Precision Oncology Pipeline – – Recently Completed Financing Supports Broad Investment Across Pipeline – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2020 and pro

• Chimerix to Report Fourth Quarter and Year End 2020 Financial Results and Provide an Operational Update on February 25, 2021

  2/18/2021

  Chimerix announced that it will host a live conference call and audio webcast on Thursday, February 25, 2021 at 8:30 a.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2020, and to provide a business overview.

• Chimerix Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

  1/25/2021

  Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced today the closing of its previously announced underwritten public offering of common stock. Prior to the closing, the underwriters exercised in full their option to purchase an additional 1,764,750 shares of common stock. As a result, the Company issued a total of 13,529,750 shares i